Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PYC TherapeuticsASX:PYC +11.25%28 Cyclically Adjusted PS Ratio is 157.06 as of Sep. 18, 2026, which is 555% above its 10-year median of 23.99. GuruFocus rates ASX:PYC with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 532 Biotechnology companies, PYC Therapeutics ranks worse than 187969.74% on this metric.
The historical rank and industry rank for PYC Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past 13 years, PYC Therapeutics's highest Cyclically Adjusted PS Ratio was 83.00. The lowest was 4.69. And the median was 23.99.
ASX:PYC's Cyclically Adjusted PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 5.78 * Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
PYC Therapeutics's adjusted revenue per share data of for the fiscal year that ended in Jun26 was A$0.000. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is A$0.02 for the trailing ten years ended in Jun26.
Shiller PE for Stocks: The True Measure of Stock Valuation
PYC Therapeutics (ASX:PYC) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
PYC Therapeutics Cyclically Adjusted PS Ratio Related Terms
PYC Therapeutics Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for PYC Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PYC Therapeutics Cyclically Adjusted PS Ratio Chart
ASX:PYC vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, PYC Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PYC Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PYC Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where PYC Therapeutics's Cyclically Adjusted PS Ratio falls into.
PYC Therapeutics Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
PYC Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 157.06 mean?
PYC Therapeutics (ASX:PYC) has a Cyclically Adjusted PS Ratio of 157.06 as of Sep. 18, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on PYC Therapeutics and its competitors. This is 555% above median its historical median of 23.99. Over the past decade, PYC Therapeutics' Cyclically Adjusted PS Ratio has ranged from 4.69 to 83.00. According to the industry distribution chart, PYC Therapeutics ranks #999999 out of 532 companies in the Biotechnology industry.
Is PYC Therapeutics' Cyclically Adjusted PS Ratio too high?
PYC Therapeutics' current Cyclically Adjusted PS Ratio of 157.06 is 555% above median its 10-year median of 23.99. Over the past 10 years, this metric has ranged from a low of 4.69 to a high of 83.00. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.78. PYC Therapeutics' value of 157.06 is 2617.3% above this industry median. Based on the distribution chart, PYC Therapeutics ranks #999999 out of 532 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PYC Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does PYC Therapeutics' Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PYC Therapeutics ranks #999999 out of 532 companies for Cyclically Adjusted PS Ratio. This places PYC Therapeutics in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.78. PYC Therapeutics' value of 157.06 is 2617.3% above this benchmark. Historically, PYC Therapeutics' own Cyclically Adjusted PS Ratio has ranged from 4.69 to 83.00 over the past decade. While the company's 10-year median is 23.99 vs. the industry median of 5.78, PYC Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.78, based on 532 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PYC Therapeutics's current Cyclically Adjusted PS Ratio of 157.06 is 2617.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on PYC Therapeutics and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PYC Therapeutics's current Cyclically Adjusted PS Ratio is 157.06, which is 555% above median its own 10-year median of 23.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PYC Therapeutics stock overvalued right now?
PYC Therapeutics (ASX:PYC) has a current Cyclically Adjusted PS Ratio of 157.06. The current Cyclically Adjusted PS Ratio is 157.06, which is 555% above median its 10-year median of 23.99 and 2617.3% above the Biotechnology industry median of 5.78. PYC Therapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current Cyclically Adjusted PS Ratio is 157.06 as of Sep. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
28GF Score
Get the complete analysis for ASX:PYC
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PYC has been successfully added to your 
